Reporte»In: Systematic Review on Acute Treatments for Episodic Migraine: Surveillance Reports [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Jul.
This report is the third and final surveillance report for the Agency for Healthcare Research and Quality (AHRQ) 2020 report Acute Treatments for Episodic Migraine (available at https://effectivehealthcare.ahrq.gov/products/migraine-treatments/research) and covers the time period from December 31, 2021, through March 21, 2022. The original 2020 report examined the evidence on the comparative effectiveness and harms of opioids as well as nonopioid pharmacologic and nonpharmacologic treatments to provide the full range of evidence to inform clinical decision making about the acute treatment of migraine. The objectives of this surveillance report are to identify the latest evidence published since the last surveillance report as of December 30, 2021 (Surveillance Report 2), and to determine how the new evidence impacts the findings of the 2020 report and surveillance reports. This is the final surveillance report planned for this systematic review.
Reporte»In: Systematic Review on Acute Treatments for Episodic Migraine: Surveillance Reports [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Jul.
This report is the second surveillance report for the Agency for Healthcare Research and Quality (AHRQ) 2020 report Acute Treatments for Episodic Migraine (available at https://effectivehealthcare.ahrq.gov/products/migraine-treatments/research) and covers the time period from September 2, 2021, through December 30, 2021. The original 2020 report examined the evidence on the comparative effectiveness and harms of opioids as well as nonopioid pharmacologic and nonpharmacologic treatments to provide the full range of evidence to inform clinical decision making about the acute treatment of migraine. The objectives of this surveillance report are to identify the latest evidence published since the last surveillance report as of September 2, 2021 (Surveillance Report 1), and to determine how the new evidence impacts the findings of the 2020 report and surveillance report. Another update is planned for June 2022 (based on evidence published from January to March 2022).
OBJECTIVES: To evaluate the effectiveness and comparative effectiveness of pharmacologic and nonpharmacologic therapies for the acute treatment of episodic migraine in adults.
DATA SOURCES: MEDLINE<sup> R</sup>, Embase<sup> R</sup>, Cochrane Central Registrar of Controlled Trials, Cochrane Database of Systematic Reviews, PsycINFO<sup> R</sup>, Scopus, and various grey literature sources from database inception to July 24, 2020. Comparative effectiveness evidence about triptans and nonsteroidal anti-inflammatory drugs (NSAIDs) was extracted from existing systematic reviews.
REVIEW METHODS: We included randomized controlled trials (RCTs) and comparative observational studies that enrolled adults who received an intervention to acutely treat episodic migraine. Pairs of independent reviewers selected and appraised studies.
RESULTS: Data on triptans were derived from 186 RCTs summarized in nine systematic reviews (101,276 patients; most studied was sumatriptan, followed by zolmitriptan, eletriptan, naratriptan, almotriptan, rizatriptan, and frovatriptan). Compared with placebo, triptans resolved pain at 2 hours and 1 day, and increased the risk of mild and transient adverse events (high strength of the body of evidence [SOE]). Data on NSAIDs were derived from five systematic reviews (13,214 patients; most studied was ibuprofen, followed by diclofenac and ketorolac). Compared with placebo, NSAIDs probably resolved pain at 2 hours and 1 day, and increased the risk of mild and transient adverse events (moderate SOE). For other interventions, we included 135 RCTs and 6 comparative observational studies (37,653 patients). Compared with placebo, antiemetics (low SOE), dihydroergotamine (moderate to high SOE), ergotamine plus caffeine (moderate SOE), and acetaminophen (moderate SOE) reduced acute pain. Opioids were evaluated in 15 studies (2,208 patients). Butorphanol, meperidine, morphine, hydromorphone, and tramadol in combination with acetaminophen may reduce pain at 2 hours and 1 day, compared with placebo (low SOE). Some opioids may be less effective than some antiemetics or dexamethasone (low SOE). No studies evaluated instruments for predicting risk of opioid misuse, opioid use disorder, or overdose, or evaluated risk mitigation strategies to be used when prescribing opioids for the acute treatment of episodic migraine. Calcitonin gene-related peptide (CGRP) receptor antagonists improved headache relief at 2 hours and increased the likelihood of being headache-free at 2 hours, at 1 day, and at 1 week (low to high SOE). Lasmiditan (the first approved 5-HT1F receptor agonist) restored function at 2 hours and resolved pain at 2 hours, 1 day, and 1 week (moderate to high SOE). Sparse and low SOE suggested possible effectiveness of dexamethasone, dipyrone, magnesium sulfate, and octreotide. Compared with placebo, several nonpharmacologic treatments may improve various measures of pain, including remote electrical neuromodulation (moderate SOE), magnetic stimulation (low SOE), acupuncture (low SOE), chamomile oil (low SOE), external trigeminal nerve stimulation (low SOE), and eye movement desensitization re-processing (low SOE). However, these interventions, including the noninvasive neuromodulation devices, have been evaluated only by single or very few trials.
CONCLUSIONS: A number of acute treatments for episodic migraine exist with varying degrees of evidence for effectiveness and harms. Use of triptans, NSAIDs, antiemetics, dihydroergotamine, CGRP antagonists, and lasmiditan is associated with improved pain and function. The evidence base for many other interventions for acute treatment, including opioids, remains limited.
Reporte»In: Systematic Review on Acute Treatments for Episodic Migraine: Surveillance Reports [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Jul.
This report is the first update for the Agency for Healthcare Research and Quality (AHRQ) 2020 report Acute Treatments for Episodic Migraine (available at https://effectivehealthcare.ahrq.gov/products/migraine-treatments/research) and covers the time period from July 2020 through September 2021. The original 2020 report examined the evidence on the comparative effectiveness and harms of opioids as well as nonopioid pharmacologic and nonpharmacologic treatments to provide the full range of evidence to inform clinical decision making about the acute treatment of migraine. The objective of this update is to identify the latest evidence published since the 2020 report and to determine how the new evidence impacts the findings of the 2020 report. Subsequent updates are planned for March 2022 (based on evidence published from October to December 2021) and June 2022 (based on evidence published from January to March 2022).
This report is the third and final surveillance report for the Agency for Healthcare Research and Quality (AHRQ) 2020 report Acute Treatments for Episodic Migraine (available at https://effectivehealthcare.ahrq.gov/products/migraine-treatments/research) and covers the time period from December 31, 2021, through March 21, 2022. The original 2020 report examined the evidence on the comparative effectiveness and harms of opioids as well as nonopioid pharmacologic and nonpharmacologic treatments to provide the full range of evidence to inform clinical decision making about the acute treatment of migraine. The objectives of this surveillance report are to identify the latest evidence published since the last surveillance report as of December 30, 2021 (Surveillance Report 2), and to determine how the new evidence impacts the findings of the 2020 report and surveillance reports. This is the final surveillance report planned for this systematic review.
